B9P0 logo

NovaBay Pharmaceuticals DB:B9P0 Stock Report

Last Price

€2.80

Market Cap

€2.3m

7D

0%

1Y

n/a

Updated

27 Aug, 2024

Data

Company Financials +

NovaBay Pharmaceuticals, Inc.

DB:B9P0 Stock Report

Market Cap: €2.3m

B9P0 Stock Overview

Develops and sells eyecare and wound care products in the United States and internationally.

B9P0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health2/6
Dividends0/6

NovaBay Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NovaBay Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.80
52 Week HighUS$5.67
52 Week LowUS$2.27
Beta0.83
11 Month Change0%
3 Month Change-34.96%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO1.27%

Recent News & Updates

Recent updates

Shareholder Returns

B9P0DE PharmaceuticalsDE Market
7D0%-0.9%1.1%
1Yn/a-14.1%13.5%

Return vs Industry: Insufficient data to determine how B9P0 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how B9P0 performed against the German Market.

Price Volatility

Is B9P0's price volatile compared to industry and market?
B9P0 volatility
B9P0 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement7.9%
Market Average Movement4.7%
10% most volatile stocks in DE Market10.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: B9P0's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine B9P0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200025Justin Hallnovabay.com

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.

NovaBay Pharmaceuticals, Inc. Fundamentals Summary

How do NovaBay Pharmaceuticals's earnings and revenue compare to its market cap?
B9P0 fundamental statistics
Market cap€2.26m
Earnings (TTM)-€14.94m
Revenue (TTM)€12.43m

0.2x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B9P0 income statement (TTM)
RevenueUS$13.88m
Cost of RevenueUS$5.94m
Gross ProfitUS$7.94m
Other ExpensesUS$24.63m
Earnings-US$16.68m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.41
Gross Margin57.20%
Net Profit Margin-120.16%
Debt/Equity Ratio-112.8%

How did B9P0 perform over the long term?

See historical performance and comparison